Sinovac Receives 20 Million Yuan For Hep A Vaccine From China’s MOH For Quake Victims
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Sinovac has received a 20 million yuan ($ 2.86 million) order from the Ministry of Health for its hepatitis A vaccine Healive, for the quake-affected area of Sichuan, the company announced May 27
You may also be interested in...
Sinovac To Launch New Vaccines In China; Chinese Government Biggest Purchaser
SHANGHAI - Sinovac saw increased income and profits from vaccine sales, including a first order for hepatitis vaccines placed by the Chinese government during the Sichuan earthquake in the first half of the year, according to financial results for the period ended June 30
Sinovac To Launch New Vaccines In China; Chinese Government Biggest Purchaser
SHANGHAI - Sinovac saw increased income and profits from vaccine sales, including a first order for hepatitis vaccines placed by the Chinese government during the Sichuan earthquake in the first half of the year, according to financial results for the period ended June 30
Sinovac CEO Weidong Yin On China’s Evolving Vaccine Market: An Interview With PharmAsia News
Sinovac Biotech CEO Weidong Yin recently spoke with PharmAsia News' Shanghai bureau about the Chinese vaccine market and the impact of current government policies on vaccine makers. Sinovac was established in April 2001 as a result of a joint venture between Sino Pharma, Shenzhen Kexing and Tangshan Yian. The Beijing-based company manufactured its first hepatitis A vaccine and sold its first dose in 2002. In December 2004, it was listed on the American Stock Exchange.